Biotech | March 12, 2022
BioPharma’s Herceptin biosimilar Phase 3 results positive
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
he financing was significantly oversubscribed with high demand from both existing and new investors.
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The facility will manufacture its Herceptin biosimilar, Tuznue
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Subscribe To Our Newsletter & Stay Updated
